On Demand: Harnessing the Power of Immunotherapy in HCC and BTC: An Expert Exploration of the Past, Present, and Future of Checkpoint Inhibition
This session will review the totality of emerging evidence for immune checkpoint inhibitors (ICIs) in the hepatocellular carcinoma (HCC) and biliary tract cancer (BTC) management calculus. Faculty will highlight the paradigmatic change ICIs have achieved, emphasize key teaching points for real-world use, and evaluate adaptive clinical trial designs and study schemas being used to investigate ICI-based treatment regimens in HCC and BTC on a prospective basis.
Immuno-oncology (IO) specialty clinicians and researchers.
- Describe the fundamental contribution of immune system dysregulation to the pathophysiology of hepatocellular carcinoma (HCC) and biliary tract cancer (BTC).
- Explain the pharmacologic rationale for integrating immune checkpoint inhibition into the HCC/BTC armamentarium.
- Review practical aspects of using immune checkpoint inhibitors (ICIs) in HCC/BTC, including dosing, approved indications, and immune-mediated adverse event (imAE) mitigation and management strategies.
- Appraise the rapidly evolving clinical trial evidentiary base and regulatory landscape for ICI-based regimens in HCC and BTC, with an emphasis on current expert consensus guideline recommendations.
- Evaluate clinical trial designs and study schemas for ICI-based treatments in HCC and BTC, focusing on established pivotal readouts and prominent prospective studies.
Organization Statement – The Harnessing the Power of Immunotherapy in HCC and BTC: An Expert Exploration of the Past, Present, and Future of Checkpoint Inhibition content and views expressed therein are those of Creative Educational Concepts and not of SITC.
Presented by Creative Educational Concepts, LLC.
Supported through an independent educational grant from AstraZeneca.
|11:45 AM-12:00 PM||Registration|
|12:00-12:05 PM||Welcome and Introductions/Pre-test|
|James J. Harding, MD|
|12:05-12:15 PM||Pathophysiologic Foundations in HCC/BTC: Immune System Etiologies and Therapeutic Targets|
|James J. Harding, MD|
|12:15-12:30 PM||Principles of Paradigm Change: Pharmacologic Rationale for ICI Utility in HCC and BTC|
|R. Katie Kelley, MD|
|12:30-12:45 PM||Bench to Bedside in HCC/BTC: Evolving Evidence, Current Guidelines, and Prospective Research|
|Strategies in the Era of Immunotherapy|
|Riad Salem, MD, MBA|
|12:45-1:00 PM||Practical Pearls for the Clinician Using ICIs in HCC and BTC/Audience Q&A/Post-test|
|Faculty Panel Moderated by James J. Harding, MD|
James J. Harding, MD
Gastrointestinal Oncology Service
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, NY
R. Katie Kelley, MD
Professor of Clinical Medicine
Department of Medicine (Hematology/Oncology)
University of California, San Francisco
San Francisco, CA
Riad Salem, MD, MBA
Professor of Radiology, Medicine and Surgery
Chief, Section of Vascular and Interventional Radiology
Vice-Chair, Image-Guided Therapy
Department of Radiology
It is the policy of Creative Educational Concepts, LLC, (CEC) to ensure independence, balance, objectivity, and scientific rigor and integrity in all their CME/CE activities. Activity planners, faculty, peer reviewers, and CEC staff must disclose to the participants any relationships with ineligible entities whose products or devices may be mentioned in this CE activity, or with the commercial supporter of this CE activity. An ineligible entity is defined as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Financial relationships may include research grants, consultant fees, travel, advisory boards, consultancy, speakers’ bureaus, other benefits, or having a self-managed equity interest in a company.
CEC has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
James J. Harding, MD–has disclosed that he receives research support from Boehringer Ingelheim, Bristol Myers Squib, Codiak, CytomX, Eli Lilly, Genoscience, Incyte, Loxo @ Lilly, Novartis, Polaris, and Yiviv. He is also an advisor or consultant to Bristol Myers Squib, Eisai, Exelexis, Hepion, Imvax, Medivir, QED, and Zymewor.
R. Katie Kelley, MD–has disclosed that she receives research support from Agios, AstraZeneca, Bayer, Bristol Myers Squibb, Eli Lilly, EMD Serono, Exelixis, Genentech/Roche, LOXO oncology, Merck, Novartis, QED therapeutics, Relay Therapeutics, Surface Oncology, and Taiho. She also is an advisor or consultant to Exact Sciences and Kinnate. She is an advisor or consultant to Agios, AstraZeneca, Exelixis, Ipsen, and Merck with compensation to her institution and her institution receives grant funding from Partner Therapeutics.
Riad Salem, MD, MBA–has disclosed that he is an advisor or consultant to AstraZeneca, Autem, Bard, Boston Scientific, Cook, Eisai, Genentech, Merck, and Merit.
Darren Cowzer, MD–has no relevant financial relationships to disclose in relation to the content of this activity.
Susan H. Gitzinger, PharmD, MPA–has no relevant financial relationships to disclose in relation to the content of this activity.
Rebecca Weaver, CHCP–has no relevant financial relationships to disclose in relation to the content of this activity.
Faculty of this CME/CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices. CEC, the faculty, and any commercial supporter of this activity do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.
In support of improving patient care, Creative Educational Concepts is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
CEC designates this live educational activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Upon completion of a CE Request Form, statements of credit for physicians will be issued within 30 business days.
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation